Intervention Review

You have free access to this content

Sertraline versus other antidepressive agents for depression

  1. Andrea Cipriani1,*,
  2. Teresa La Ferla2,
  3. Toshi A Furukawa3,
  4. Alessandra Signoretti1,
  5. Atsuo Nakagawa4,
  6. Rachel Churchill5,
  7. Hugh McGuire6,
  8. Corrado Barbui1

Editorial Group: Cochrane Common Mental Disorders Group

Published Online: 14 APR 2010

Assessed as up-to-date: 30 JUN 2008

DOI: 10.1002/14651858.CD006117.pub4


How to Cite

Cipriani A, La Ferla T, Furukawa TA, Signoretti A, Nakagawa A, Churchill R, McGuire H, Barbui C. Sertraline versus other antidepressive agents for depression. Cochrane Database of Systematic Reviews 2010, Issue 4. Art. No.: CD006117. DOI: 10.1002/14651858.CD006117.pub4.

Author Information

  1. 1

    University of Verona, Department of Medicine and Public Health, Section of Psychiatry and Clinical Psychology, Verona, Italy

  2. 2

    University of Perugia, Department of Clinical and Experimental Medicine, Section of Psychiatry, Perugia, Italy

  3. 3

    Nagoya City University Graduate School of Medical Sciences, Department of Psychiatry & Cognitive-Behavioral Medicine, Nagoya, Aichi, Japan

  4. 4

    Keio University School of Medicine, Department of Psychiatry, Tokyo, Japan

  5. 5

    University of Bristol, Academic Unit of Psychiatry, Community Based Medicine, Bristol, Avon, UK

  6. 6

    National Collaborating Centre for Women's and Children's Health, London, UK

*Andrea Cipriani, Department of Medicine and Public Health, Section of Psychiatry and Clinical Psychology, University of Verona, Policlinico "G.B.Rossi", Piazzale L.A. Scuro, 10, Verona, 37134, Italy. andrea.cipriani@univr.it. andrea.cipriani@psych.ox.ac.uk.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 14 APR 2010

SEARCH

[Figure 1]
Figure 1. Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.
[Figure 2]
Figure 2. Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
[Figure 3]
Figure 3. Forest plot of comparison: 1 Failure to respond at endpoint (6 - 12 weeks), outcome: 1.1 Sertraline versus TCAs.
[Figure 4]
Figure 4. Forest plot of comparison: 4 Failure to remission at endpoint (6 - 12 weeks), outcome: 4.1 Sertraline versus TCAs.
[Figure 5]
Figure 5. Forest plot of comparison: 7 Standardised mean difference at endpoint (6 - 12 weeks), outcome: 7.1 Sertraline versus TCAs.
[Figure 6]
Figure 6. Forest plot of comparison: 10 Failure to complete (any cause), outcome: 10.1 Sertraline versus TCAs.
[Figure 7]
Figure 7. Forest plot of comparison: 1 Failure to respond at endpoint (6 - 12 weeks), outcome: 1.2 Sertraline versus Heterocyclics.
[Figure 8]
Figure 8. Forest plot of comparison: 4 Failure to remission at endpoint (6 - 12 weeks), outcome: 4.2 Sertraline versus Heterocyclics.
[Figure 9]
Figure 9. Forest plot of comparison: 7 Standardised mean difference at endpoint (6 - 12 weeks), outcome: 7.2 Sertraline versus Heterocyclics.
[Figure 10]
Figure 10. Forest plot of comparison: 1 Failure to respond at endpoint (6 - 12 weeks), outcome: 1.3 Sertraline versus other SSRIs.
[Figure 11]
Figure 11. Forest plot of comparison: 4 Failure to remission at endpoint (6 - 12 weeks), outcome: 4.3 Sertraline versus other SSRIs.
[Figure 12]
Figure 12. Forest plot of comparison: 7 Standardised mean difference at endpoint (6 - 12 weeks), outcome: 7.3 Sertraline versus other SSRIs.
[Figure 13]
Figure 13. Forest plot of comparison: 10 Failure to complete (any cause), outcome: 10.3 Sertraline versus other SSRIs.
[Figure 14]
Figure 14. Forest plot of comparison: 1 Failure to respond at endpoint (6 - 12 weeks), outcome: 1.4 Sertraline versus newer ADs.
[Figure 15]
Figure 15. Forest plot of comparison: 4 Failure to remission at endpoint (6 - 12 weeks), outcome: 4.4 Sertraline versus newer ADs.
[Figure 16]
Figure 16. Forest plot of comparison: 7 Standardised mean difference at endpoint (6 - 12 weeks), outcome: 7.4 Sertraline versus newer ADs.
[Figure 17]
Figure 17. Forest plot of comparison: 10 Failure to complete (any cause), outcome: 10.4 Sertraline versus newer ADs.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Failure to respond at endpoint (6 - 12 weeks), Outcome 1 Sertraline versus TCAs.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Failure to respond at endpoint (6 - 12 weeks), Outcome 2 Sertraline versus Heterocyclics.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Failure to respond at endpoint (6 - 12 weeks), Outcome 3 Sertraline versus other SSRIs.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Failure to respond at endpoint (6 - 12 weeks), Outcome 4 Sertraline versus newer ADs.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Failure to respond (at 1 - 4 weeks), Outcome 1 Sertraline versus other SSRIs.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Failure to respond (at 1 - 4 weeks), Outcome 2 Sertraline versus newer ADs.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Failure to respond (at 16 - 24 weeks), Outcome 1 Sertraline versus TCAs.
[Analysis 3.2]
Analysis 3.2. Comparison 3 Failure to respond (at 16 - 24 weeks), Outcome 2 Sertraline versus other SSRIs.
[Analysis 3.3]
Analysis 3.3. Comparison 3 Failure to respond (at 16 - 24 weeks), Outcome 3 Sertraline versus newer ADs.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Failure to remission at endpoint (6 - 12 weeks), Outcome 1 Sertraline versus TCAs.
[Analysis 4.2]
Analysis 4.2. Comparison 4 Failure to remission at endpoint (6 - 12 weeks), Outcome 2 Sertraline versus Heterocyclics.
[Analysis 4.3]
Analysis 4.3. Comparison 4 Failure to remission at endpoint (6 - 12 weeks), Outcome 3 Sertraline versus other SSRIs.
[Analysis 4.4]
Analysis 4.4. Comparison 4 Failure to remission at endpoint (6 - 12 weeks), Outcome 4 Sertraline versus newer ADs.
[Analysis 5.1]
Analysis 5.1. Comparison 5 Failure to remission (at 1 - 4 weeks), Outcome 1 Sertraline versus other SSRIs.
[Analysis 5.2]
Analysis 5.2. Comparison 5 Failure to remission (at 1 - 4 weeks), Outcome 2 Sertraline versus newer ADs.
[Analysis 6.1]
Analysis 6.1. Comparison 6 Failure to remission (at 16 - 24 weeks), Outcome 1 Sertraline versus TCAs.
[Analysis 6.2]
Analysis 6.2. Comparison 6 Failure to remission (at 16 - 24 weeks), Outcome 2 Sertraline versus other SSRIs.
[Analysis 6.3]
Analysis 6.3. Comparison 6 Failure to remission (at 16 - 24 weeks), Outcome 3 Sertraline versus newer ADs.
[Analysis 7.1]
Analysis 7.1. Comparison 7 Standardised mean difference at endpoint (6 - 12 weeks), Outcome 1 Sertraline versus TCAs.
[Analysis 7.2]
Analysis 7.2. Comparison 7 Standardised mean difference at endpoint (6 - 12 weeks), Outcome 2 Sertraline versus Heterocyclics.
[Analysis 7.3]
Analysis 7.3. Comparison 7 Standardised mean difference at endpoint (6 - 12 weeks), Outcome 3 Sertraline versus other SSRIs.
[Analysis 7.4]
Analysis 7.4. Comparison 7 Standardised mean difference at endpoint (6 - 12 weeks), Outcome 4 Sertraline versus newer ADs.
[Analysis 8.1]
Analysis 8.1. Comparison 8 Standardised mean difference (at 1 - 4 weeks), Outcome 1 Sertraline versus TCAs.
[Analysis 8.2]
Analysis 8.2. Comparison 8 Standardised mean difference (at 1 - 4 weeks), Outcome 2 Sertraline versus Heterocyclics.
[Analysis 8.3]
Analysis 8.3. Comparison 8 Standardised mean difference (at 1 - 4 weeks), Outcome 3 Sertraline versus other SSRIs.
[Analysis 8.4]
Analysis 8.4. Comparison 8 Standardised mean difference (at 1 - 4 weeks), Outcome 4 Sertraline versus newer ADs.
[Analysis 9.1]
Analysis 9.1. Comparison 9 Standardised mean difference (at 12 - 24 weeks), Outcome 1 Sertraline versus other SSRIs.
[Analysis 9.2]
Analysis 9.2. Comparison 9 Standardised mean difference (at 12 - 24 weeks), Outcome 2 Sertraline versus newer ADs.
[Analysis 10.1]
Analysis 10.1. Comparison 10 Failure to complete (any cause), Outcome 1 Sertraline versus TCAs.
[Analysis 10.2]
Analysis 10.2. Comparison 10 Failure to complete (any cause), Outcome 2 Sertraline versus other SSRIs.
[Analysis 10.3]
Analysis 10.3. Comparison 10 Failure to complete (any cause), Outcome 3 Sertraline versus newer ADs.
[Analysis 11.1]
Analysis 11.1. Comparison 11 Failure to complete (due to inefficacy), Outcome 1 Sertraline versus TCAs.
[Analysis 11.2]
Analysis 11.2. Comparison 11 Failure to complete (due to inefficacy), Outcome 2 Sertraline versus other SSRIs.
[Analysis 11.3]
Analysis 11.3. Comparison 11 Failure to complete (due to inefficacy), Outcome 3 Sertraline versus newer ADs.
[Analysis 12.1]
Analysis 12.1. Comparison 12 Failure to complete (due to side effects), Outcome 1 Sertraline versus TCAs.
[Analysis 12.2]
Analysis 12.2. Comparison 12 Failure to complete (due to side effects), Outcome 2 Sertraline versus other SSRIs.
[Analysis 12.3]
Analysis 12.3. Comparison 12 Failure to complete (due to side effects), Outcome 3 Sertraline vs newer ADs.
[Analysis 13.1]
Analysis 13.1. Comparison 13 SE - Participants with at least one TEAE, Outcome 1 Sertraline versus TCAs.
[Analysis 13.2]
Analysis 13.2. Comparison 13 SE - Participants with at least one TEAE, Outcome 2 Sertraline versus other SSRIs.
[Analysis 13.3]
Analysis 13.3. Comparison 13 SE - Participants with at least one TEAE, Outcome 3 Sertraline versus newer ADs.
[Analysis 14.1]
Analysis 14.1. Comparison 14 SE - Agitation / Anxiety, Outcome 1 Sertraline versus TCAs.
[Analysis 14.2]
Analysis 14.2. Comparison 14 SE - Agitation / Anxiety, Outcome 2 Sertraline versus other SSRIs.
[Analysis 14.3]
Analysis 14.3. Comparison 14 SE - Agitation / Anxiety, Outcome 3 Sertraline versus newer ADs.
[Analysis 15.1]
Analysis 15.1. Comparison 15 SE - Constipation, Outcome 1 Sertraline versus TCAs.
[Analysis 15.2]
Analysis 15.2. Comparison 15 SE - Constipation, Outcome 2 Sertraline versus Heterocyclics.
[Analysis 15.3]
Analysis 15.3. Comparison 15 SE - Constipation, Outcome 3 Sertraline versus other SSRIs.
[Analysis 15.4]
Analysis 15.4. Comparison 15 SE - Constipation, Outcome 4 Sertraline versus newer ADs.
[Analysis 16.1]
Analysis 16.1. Comparison 16 SE - Diarrhoea, Outcome 1 Sertraline versus TCAs.
[Analysis 16.2]
Analysis 16.2. Comparison 16 SE - Diarrhoea, Outcome 2 Sertraline versus Heterocyclics.
[Analysis 16.3]
Analysis 16.3. Comparison 16 SE - Diarrhoea, Outcome 3 Sertraline versus other SSRIs.
[Analysis 16.4]
Analysis 16.4. Comparison 16 SE - Diarrhoea, Outcome 4 Sertraline versus newer ADs.
[Analysis 17.1]
Analysis 17.1. Comparison 17 SE - Dry Mouth, Outcome 1 Sertraline versus TCAs.
[Analysis 17.2]
Analysis 17.2. Comparison 17 SE - Dry Mouth, Outcome 2 Sertraline versus Heterocyclics.
[Analysis 17.3]
Analysis 17.3. Comparison 17 SE - Dry Mouth, Outcome 3 Sertraline versus other SSRIs.
[Analysis 17.4]
Analysis 17.4. Comparison 17 SE - Dry Mouth, Outcome 4 Sertraline versus newer ADs.
[Analysis 18.1]
Analysis 18.1. Comparison 18 SE - Hypotension, Outcome 1 Sertraline versus TCAs.
[Analysis 18.2]
Analysis 18.2. Comparison 18 SE - Hypotension, Outcome 2 Sertraline versus Heterocyclics.
[Analysis 19.1]
Analysis 19.1. Comparison 19 SE - Insomnia, Outcome 1 Sertraline versus TCAs.
[Analysis 19.2]
Analysis 19.2. Comparison 19 SE - Insomnia, Outcome 2 Sertraline versus Heterocyclics.
[Analysis 19.3]
Analysis 19.3. Comparison 19 SE - Insomnia, Outcome 3 Sertraline versus other SSRIs.
[Analysis 19.4]
Analysis 19.4. Comparison 19 SE - Insomnia, Outcome 4 Sertraline versus newer ADs.
[Analysis 20.1]
Analysis 20.1. Comparison 20 SE - Nausea, Outcome 1 Sertraline versus TCAs.
[Analysis 20.2]
Analysis 20.2. Comparison 20 SE - Nausea, Outcome 2 Sertraline versus Heterocyclics.
[Analysis 20.3]
Analysis 20.3. Comparison 20 SE - Nausea, Outcome 3 Sertraline versus other SSRIs.
[Analysis 20.4]
Analysis 20.4. Comparison 20 SE - Nausea, Outcome 4 Sertraline versus newer ADs.
[Analysis 21.1]
Analysis 21.1. Comparison 21 SE - Sleepiness / Drowsiness, Outcome 1 Sertraline versus TCAs.
[Analysis 21.2]
Analysis 21.2. Comparison 21 SE - Sleepiness / Drowsiness, Outcome 2 Sertraline versus Heterocyclics.
[Analysis 21.3]
Analysis 21.3. Comparison 21 SE - Sleepiness / Drowsiness, Outcome 3 Sertraline versus other SSRIs.
[Analysis 21.4]
Analysis 21.4. Comparison 21 SE - Sleepiness / Drowsiness, Outcome 4 Sertraline versus newer ADs.
[Analysis 22.1]
Analysis 22.1. Comparison 22 SE - Urinary problems, Outcome 1 Sertraline versus TCAs.
[Analysis 22.2]
Analysis 22.2. Comparison 22 SE - Urinary problems, Outcome 2 Sertraline versus Heterocyclics.
[Analysis 22.3]
Analysis 22.3. Comparison 22 SE - Urinary problems, Outcome 3 Sertraline versus other SSRIs.
[Analysis 22.4]
Analysis 22.4. Comparison 22 SE - Urinary problems, Outcome 4 Sertraline versus newer ADs.
[Analysis 23.1]
Analysis 23.1. Comparison 23 SE - Vomiting, Outcome 1 Sertraline versus TCAs.
[Analysis 23.2]
Analysis 23.2. Comparison 23 SE - Vomiting, Outcome 2 Sertraline versus newer ADs.
[Analysis 24.1]
Analysis 24.1. Comparison 24 SE - Appetite increase, Outcome 1 Sertraline versus TCAs.
[Analysis 24.2]
Analysis 24.2. Comparison 24 SE - Appetite increase, Outcome 2 Sertraline versus newer ADs.
[Analysis 25.1]
Analysis 25.1. Comparison 25 SE - Appetite loss / Anorexia, Outcome 1 Sertraline versus TCAs.
[Analysis 25.2]
Analysis 25.2. Comparison 25 SE - Appetite loss / Anorexia, Outcome 2 Sertraline versus other SSRIs.
[Analysis 25.3]
Analysis 25.3. Comparison 25 SE - Appetite loss / Anorexia, Outcome 3 Sertraline versus newer ADs.
[Analysis 26.1]
Analysis 26.1. Comparison 26 SE - Depression, Outcome 1 Sertraline versus TCAs.
[Analysis 26.2]
Analysis 26.2. Comparison 26 SE - Depression, Outcome 2 Sertraline versus other SSRIs.
[Analysis 26.3]
Analysis 26.3. Comparison 26 SE - Depression, Outcome 3 Sertraline versus newer ADs.
[Analysis 27.1]
Analysis 27.1. Comparison 27 SE - Dermatological Problems, Outcome 1 Sertraline versus TCAs.
[Analysis 27.2]
Analysis 27.2. Comparison 27 SE - Dermatological Problems, Outcome 2 Sertraline versus other SSRIs.
[Analysis 27.3]
Analysis 27.3. Comparison 27 SE - Dermatological Problems, Outcome 3 Sertraline versus newer ADs.
[Analysis 28.1]
Analysis 28.1. Comparison 28 SE - Dismenorrea, Outcome 1 Sertraline versus newer ADs.
[Analysis 29.1]
Analysis 29.1. Comparison 29 SE - Dizziness, Outcome 1 Sertraline versus TCAs.
[Analysis 29.2]
Analysis 29.2. Comparison 29 SE - Dizziness, Outcome 2 Sertraline versus Heterocyclics.
[Analysis 29.3]
Analysis 29.3. Comparison 29 SE - Dizziness, Outcome 3 Sertraline versus other SSRIs.
[Analysis 29.4]
Analysis 29.4. Comparison 29 SE - Dizziness, Outcome 4 Sertraline versus newer ADs.
[Analysis 30.1]
Analysis 30.1. Comparison 30 SE - Gastrointestinal symptoms and dyspepsia, Outcome 1 Sertraline versus TCAs.
[Analysis 30.2]
Analysis 30.2. Comparison 30 SE - Gastrointestinal symptoms and dyspepsia, Outcome 2 Sertraline versus other SSRIs.
[Analysis 30.3]
Analysis 30.3. Comparison 30 SE - Gastrointestinal symptoms and dyspepsia, Outcome 3 Sertraline versus newer ADs.
[Analysis 31.1]
Analysis 31.1. Comparison 31 SE - Fatigue, Outcome 1 Sertraline versus TCAs.
[Analysis 31.2]
Analysis 31.2. Comparison 31 SE - Fatigue, Outcome 2 Sertraline versus other SSRIs.
[Analysis 31.3]
Analysis 31.3. Comparison 31 SE - Fatigue, Outcome 3 Sertraline versus newer ADs.
[Analysis 32.1]
Analysis 32.1. Comparison 32 SE - Flu Syndrome, Outcome 1 Sertraline versus other SSRIs.
[Analysis 32.2]
Analysis 32.2. Comparison 32 SE - Flu Syndrome, Outcome 2 Sertraline versus newer ADs.
[Analysis 33.1]
Analysis 33.1. Comparison 33 SE - Headache, Outcome 1 Sertraline versus TCAs.
[Analysis 33.2]
Analysis 33.2. Comparison 33 SE - Headache, Outcome 2 Sertraline versus other SSRIs.
[Analysis 33.3]
Analysis 33.3. Comparison 33 SE - Headache, Outcome 3 Sertraline versus newer ADs.
[Analysis 34.1]
Analysis 34.1. Comparison 34 SE - Manic State, Outcome 1 Sertraline versus TCAs.
[Analysis 34.2]
Analysis 34.2. Comparison 34 SE - Manic State, Outcome 2 Sertraline versus other SSRIs.
[Analysis 35.1]
Analysis 35.1. Comparison 35 SE - Nervousness and restlessness, Outcome 1 Sertraline versus TCAs.
[Analysis 35.2]
Analysis 35.2. Comparison 35 SE - Nervousness and restlessness, Outcome 2 Sertraline versus other SSRIs.
[Analysis 35.3]
Analysis 35.3. Comparison 35 SE - Nervousness and restlessness, Outcome 3 Sertraline versus newer ADs.
[Analysis 36.1]
Analysis 36.1. Comparison 36 SE - Ophthalmological problems (abnormal/blurred vision), Outcome 1 Sertraline versus TCAs.
[Analysis 36.2]
Analysis 36.2. Comparison 36 SE - Ophthalmological problems (abnormal/blurred vision), Outcome 2 Sertraline versus other SSRIs.
[Analysis 36.3]
Analysis 36.3. Comparison 36 SE - Ophthalmological problems (abnormal/blurred vision), Outcome 3 Sertraline versus newer ADs.
[Analysis 37.1]
Analysis 37.1. Comparison 37 SE - Pain, Outcome 1 Sertraline versus TCAs.
[Analysis 37.2]
Analysis 37.2. Comparison 37 SE - Pain, Outcome 2 Sertraline versus other SSRIs.
[Analysis 37.3]
Analysis 37.3. Comparison 37 SE - Pain, Outcome 3 Sertraline versus newer ADs.
[Analysis 38.1]
Analysis 38.1. Comparison 38 SE - Palpitations / Tachycardia, Outcome 1 Sertraline versus TCAs.
[Analysis 38.2]
Analysis 38.2. Comparison 38 SE - Palpitations / Tachycardia, Outcome 2 Sertraline versus Heterocyclics.
[Analysis 38.3]
Analysis 38.3. Comparison 38 SE - Palpitations / Tachycardia, Outcome 3 Sertraline versus other SSRIs.
[Analysis 38.4]
Analysis 38.4. Comparison 38 SE - Palpitations / Tachycardia, Outcome 4 Sertraline versus newer ADs.
[Analysis 39.1]
Analysis 39.1. Comparison 39 SE - Peripheral Nervous System + CNS problems, Outcome 1 Sertraline versus TCAs.
[Analysis 39.2]
Analysis 39.2. Comparison 39 SE - Peripheral Nervous System + CNS problems, Outcome 2 Sertraline versus other SSRIs.
[Analysis 39.3]
Analysis 39.3. Comparison 39 SE - Peripheral Nervous System + CNS problems, Outcome 3 Sertraline versus newer ADs.
[Analysis 40.1]
Analysis 40.1. Comparison 40 SE - Psychosis and other psychiatric problems, Outcome 1 Sertraline versus TCAs.
[Analysis 40.2]
Analysis 40.2. Comparison 40 SE - Psychosis and other psychiatric problems, Outcome 2 Sertraline versus other SSRIs.
[Analysis 40.3]
Analysis 40.3. Comparison 40 SE - Psychosis and other psychiatric problems, Outcome 3 Sertraline versus newer ADs.
[Analysis 41.1]
Analysis 41.1. Comparison 41 SE - Rhinitis, Outcome 1 Sertraline versus other SSRIs.
[Analysis 41.2]
Analysis 41.2. Comparison 41 SE - Rhinitis, Outcome 2 Sertraline versus newer ADs.
[Analysis 42.1]
Analysis 42.1. Comparison 42 SE - Sexual problems (general and libido decreased), Outcome 1 Sertraline versus TCAs.
[Analysis 42.2]
Analysis 42.2. Comparison 42 SE - Sexual problems (general and libido decreased), Outcome 2 Sertraline versus other SSRIs.
[Analysis 42.3]
Analysis 42.3. Comparison 42 SE - Sexual problems (general and libido decreased), Outcome 3 Sertraline versus newer ADs.
[Analysis 43.1]
Analysis 43.1. Comparison 43 SE - Sexual problems (anorgasmia or impotence), Outcome 1 Sertraline versus other SSRIs.
[Analysis 43.2]
Analysis 43.2. Comparison 43 SE - Sexual problems (anorgasmia or impotence), Outcome 2 Sertraline versus newer ADs.
[Analysis 44.1]
Analysis 44.1. Comparison 44 SE - Sexual problems (ejaculation disorder or erectile dysfunction), Outcome 1 Sertraline versus other SSRIs.
[Analysis 44.2]
Analysis 44.2. Comparison 44 SE - Sexual problems (ejaculation disorder or erectile dysfunction), Outcome 2 Sertraline versus newer ADs.
[Analysis 45.1]
Analysis 45.1. Comparison 45 SE - Sweating Increased, Outcome 1 Sertraline versus TCAs.
[Analysis 45.2]
Analysis 45.2. Comparison 45 SE - Sweating Increased, Outcome 2 Sertraline versus Heterocyclics.
[Analysis 45.3]
Analysis 45.3. Comparison 45 SE - Sweating Increased, Outcome 3 Sertraline versus other SSRIs.
[Analysis 45.4]
Analysis 45.4. Comparison 45 SE - Sweating Increased, Outcome 4 Sertraline versus newer ADs.
[Analysis 46.1]
Analysis 46.1. Comparison 46 SE - Tremor, Outcome 1 Sertraline versus TCAs.
[Analysis 46.2]
Analysis 46.2. Comparison 46 SE - Tremor, Outcome 2 Sertraline versus Heterocyclics.
[Analysis 46.3]
Analysis 46.3. Comparison 46 SE - Tremor, Outcome 3 Sertraline versus other SSRIs.
[Analysis 46.4]
Analysis 46.4. Comparison 46 SE - Tremor, Outcome 4 Sertraline versus newer ADs.
[Analysis 47.1]
Analysis 47.1. Comparison 47 SE - Weight gain, Outcome 1 Sertraline versus TCAs.
[Analysis 47.2]
Analysis 47.2. Comparison 47 SE - Weight gain, Outcome 2 Sertraline versus newer ADs.
[Analysis 48.1]
Analysis 48.1. Comparison 48 SE - Weight loss, Outcome 1 Sertraline versus TCAs.
[Analysis 48.2]
Analysis 48.2. Comparison 48 SE - Weight loss, Outcome 2 Sertraline versus other SSRIs.
[Analysis 49.1]
Analysis 49.1. Comparison 49 Deaths, suicide and suicidality, Outcome 1 Suicide - Tendency/Ideation.
[Analysis 49.2]
Analysis 49.2. Comparison 49 Deaths, suicide and suicidality, Outcome 2 Suicide - Attempted.
[Analysis 49.3]
Analysis 49.3. Comparison 49 Deaths, suicide and suicidality, Outcome 3 Suicide - Completed.